- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07540624
Eficacia de los Enjuagues Bucales de Clorhexidina y Morus Nigra Tras el Tratamiento Periodontal
Comparación de la eficacia de los colutorios de clorhexidina y Morus Nigra en el tratamiento de enfermedades periodontales
This study aims to evaluate and compare the clinical, biochemical, and microbiological effects of chlorhexidine and Morus nigra mouthwashes used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with periodontal diseases. The participants will be divided into three groups: a control group receiving only SRP, a group receiving SRP combined with chlorhexidine mouthwash, and a group receiving SRP combined with Morus nigra mouthwash. Clinical periodontal parameters, gingival crevicular fluid levels of inflammatory markers (including TNF-a, IL-1b, and IL-10), and subgingival plaque microbiological profiles (such as red complex bacteria and Fusobacterium) will be evaluated at baseline, 1 month, and 3 months after the treatment.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Malatya
-
Battalgazi, Malatya, Turquía (Türkiye), 44300
- Inonu University Faculty of Dentistry
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients diagnosed with periodontitis.
- Systemically healthy individuals.
- Patients aged between 18 and 65 years.
- Presence of at least 20 natural teeth.
- Volunteering to participate in the study and signing the informed consent form.
Exclusion Criteria:
- Presence of any systemic disease that may affect periodontal health or systemic inflammatory response (e.g., Diabetes Mellitus, immunological disorders).
- Current smokers or use of any tobacco products.
- Pregnancy or lactation.
- Use of systemic antibiotics, anti-inflammatory drugs, or immunosuppressive medications within the last 6 months.
- Having received any non-surgical or surgical periodontal treatment within the last 6 months.
- Known allergy or sensitivity to chlorhexidine or Morus nigra (blackberry) extracts.
- Patients using orthodontic appliances.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Control Group
Non-surgical periodontal treatment consisting of full-mouth scaling and root planing (SRP) using ultrasonic and hand instruments. |
All patients in the study underwent non-surgical periodontal therapy consisting of full-mouth scaling and root planing (SRP) using both ultrasonic devices and hand instruments. |
|
Experimental: Chlorhexidine Group
As an adjunct to scaling and root planing, patients will rinse with 15 ml of 0.12% chlorhexidine gluconate mouthwash twice a day (morning and evening) for 1 minute. The duration of the intervention is 14 days. |
All patients in the study underwent non-surgical periodontal therapy consisting of full-mouth scaling and root planing (SRP) using both ultrasonic devices and hand instruments. As an adjunct to SRP, patients were instructed to rinse with 15 ml of 0.12% chlorhexidine gluconate mouthwash twice daily (morning and evening) for 1 minute. The treatment duration was 14 days. |
|
Experimental: Morus Nigra Group
As an adjunct to scaling and root planing, patients will rinse with 15 ml of a standardized mouthwash containing 5% Morus nigra extract twice a day (morning and evening) for 1 minute. The duration of the intervention is 14 days. |
All patients in the study underwent non-surgical periodontal therapy consisting of full-mouth scaling and root planing (SRP) using both ultrasonic devices and hand instruments. As an adjunct to SRP, patients were instructed to rinse with 15 ml of a standardized mouthwash containing 5% Morus nigra extract twice daily (morning and evening) for 1 minute. The treatment duration was 14 days. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Gingival Index (GI)
Periodo de tiempo: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
Evaluation of gingival inflammation using a scale of 0 to 3. |
Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
|
Plaque Index (PI)
Periodo de tiempo: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
Evaluation of plaque accumulation using a scale of 0 to 3. |
Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
|
Probing Depth (PD)
Periodo de tiempo: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
Measurement of the distance from the gingival margin to the bottom of the periodontal pocket. |
Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
|
Clinical Attachment Level (CAL)
Periodo de tiempo: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
Measurement of the distance from the cementoenamel junction to the bottom of the periodontal pocket. |
Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
|
Bleeding on Probing (BOP)
Periodo de tiempo: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
Evaluation of the presence or absence of bleeding within 30 seconds after probing. The result is recorded as a percentage of sites that bleed. |
Baseline (Day 0), 1 month, and 3 months after periodontal treatment.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Gingival Crevicular Fluid (GCF) Inflammatory Markers
Periodo de tiempo: At baseline, 1 month, and 3 months after treatment
|
Analysis of TNF-a, IL-1b, and IL-10 levels in the gingival crevicular fluid using ELISA (or specific biochemical assay) to evaluate the local inflammatory response |
At baseline, 1 month, and 3 months after treatment
|
|
Change in Subgingival Plaque Microbiological Profile
Periodo de tiempo: At baseline, 1 month, and 3 months after treatment
|
Evaluation of subgingival plaque samples to determine the levels of red complex bacteria and Fusobacterium nucleatum using PCR (Polymerase Chain Reaction) analysis |
At baseline, 1 month, and 3 months after treatment
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de la Boca
- Enfermedades Estomatognáticas
- Periodontitis
- Enfermedades periodontales
- Sistema digestivo y fenómenos fisiológicos orales
- Odontología
- Fenómenos fisiológicos dentales
- Escala dental
- Profilaxis dental
- Periodoncia
- Legrado subgingival
- Odontología preventiva
- Planificación de raíz
- Exfoliación Dental
Otros números de identificación del estudio
- INONU-2025/04
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data that underlie the results reported in the published article will be shared
Marco de tiempo para compartir IPD
Data will be available beginning 6 months and ending 36 months following article publication.
Criterios de acceso compartido de IPD
Data will be shared with researchers who provide a methodologically sound proposal. Requests for data sharing should be directed to the principal investigator via email
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .